Skip to main content
Erschienen in: European Journal of Medical Research 1/2023

Open Access 01.12.2023 | Research

The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis

verfasst von: Nader Salari, Hooman Ghasemi, Reza Fatahian, Kamran Mansouri, Sadat Dokaneheifard, Mohammad hossain Shiri, Mahvan Hemmati, Masoud Mohammadi

Erschienen in: European Journal of Medical Research | Ausgabe 1/2023

Abstract

Background

Primary central nervous system (CNS) tumors are a heterogeneous group of neoplasms, including benign and malignant tumors. Since there are many heterogeneities in the prevalence reported in previous studies on this type of tumor, this study was performed to determine the overall prevalence of different primary CNS tumors.

Method

The study was conducted as a systematic review and meta-analysis by searching international databases, including PubMed, Scopus, Science Direct, Web of science, and the Google Scholar search engine until August 2020. After transferring the studies to information management software (EndNote) and eliminating duplicate studies, the remaining studies were reviewed based on inclusion and exclusion criteria according to three stages of primary and secondary evaluation and qualitative evaluation. Comprehensive Meta-Analysis software, Begg, Mazumdar, and I2 tests were used for data analysis, publication bias analysis, and heterogeneity analysis, respectively.

Results

After performing the systematic review steps, 80 studies were included for final analysis. Based on 8 studies, the prevalence of brain tumors was 70.9%. Also, studies on 7 other studies showed that the prevalence of spinal tumors was 12.2%. A review of 14 studies showed that the prevalence of neuroepithelial tumors was 34.7%. The analysis of 27 studies reported a prevalence of glioma tumors of 42.8%. Analyses performed on other studies showed that the prevalence of pituitary adenomas was 12.2%, embryonal tumors 3.1%, ependymal tumors 3.2%, meningiomas 24.1%, glial tumors 0.8%, astrocytic 20.3%, oligodendroglial 3.9%, glioblastoma 17.7%, schwannoma 6.7%, medulloblastoma 7.7% and Polycystic astrocytomas 3.8%.

Conclusion

As a result, it can be stated that brain tumors are the most common type of primary CNS tumors. It was also observed that tumors involving neuroepithelial cells are more common in patients than other types of tumors.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
SID
Scientific Information Database
MESH
Medical Subject Headings
WoS
Web of Science
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analysis
STROBE
Strengthening the reporting of observational studies in epidemiology for cross-sectional study
CNS
Primary central nervous system
Studies in the field of primary central nervous system tumors are broad, and so far, no study has collected data from these extensive studies. Certainly, determining the general prevalence of nervous system tumors can make policy measures in the prevention, diagnosis, and treatment of tumors effective and reduce treatment costs.

Background

Primary tumors of the central nervous system (CNS) are a heterogeneous group of neoplasms that include benign and malignant tumors [1], which are known as tumors in the brain and spinal cord [2]. Various factors such as age, race, ethnicity, gender, environmental factors, hormones, and genetics can play a role in the etiology of CNS tumors [3]. More than 100 types of tumors that are histologically different are known as subtypes of CNS tumors. The incidence of each tumor varies with age and tissue involved. These tumors include glioma, astrocytoma, embryonal tumors, meningioma, and medulloblastoma [4]. Pituitary and pineal gland tumors are other CNS tumors [2]. The most common malignant tumor among CNS tumors is glioblastoma which has the highest mortality rate. On the other hand, meningioma is known as the most common benign tumor [5].
CNS tumors are not as common as other tumors, such as gastrointestinal cancers. However, the number of people with CNS tumors has increased over time [6]. CNS tumors are the most common type of cancer and the second leading cause of death at the age of 19 in the United States and Canada [7].
A 2020 study of 242 Indian children found that boys were more likely to be infected than girls. This study stated that the cerebellum was the most common site of tumors in the studied samples, followed by the brain’s hemispheres with the highest incidence of tumors [8].
Generally, primary malignancies account for about 2% of all cancers. About half of CNS tumors are benign. However, if benign tumors are not operable and radiotherapeutic, they can be fatal due to growth in the closed space of the skull [9]. A population-based study in 2019 stated that 5.5 out of 100.00 people develop glioma [10]. Another study in Iran stated that 6 out of 100,000 people are diagnosed with CNS tumors [11].
CNS tumors are recognized as one of the leading causes of death in children and adults [12]. In a way, these tumors are the second leading cause of death in children and the third leading cause of death in adults [9]. Also, the complications of this disease have a great impact on the individual, family, and social lifestyle of patients [13].
CNS tumors increase the pressure inside the skull or the spinal cord by stimulating or destroying adjacent nerve tissue and spreading the mass in a constant volume, which causes symptoms. A histological type of CNS tumor may show different clinical symptoms depending on the anatomical location involved. Therefore, it seems difficult to diagnose the exact type of tumor and its malignancy based on clinical signs [14].
There are several factors associated with CNS tumors that should be considered, including the choice of a new and appropriate biological treatment method and the effect of the natural history of brain development on the nature of the disease [13]. CNS tumors can cause mental alteration and neurological disorders and put a heavy burden on families and the health system [2].
Because CNS tumors are very diverse and cause different complications in different people and cause severe disabilities in a person, early diagnosis of tumor type is very important. Also, since there is a lot of heterogeneity due to previous studies on this type of tumor, the present study is conducted to investigate the prevalence of different types of primary CNS tumors.

Method

Protocol and information resources

This study was performed by systematic review method and following PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) [15], and it examines the prevalence of primary CNS tumors worldwide. The search was conducted in the following databases up to 29 August 2020: PubMed, Scopus, Science Direct, and Web of science (WoS).

Search strategy

Initially, a comprehensive study was conducted to select appropriate terms around the title. After selecting keywords appropriate to this systematic review study, a search was conducted in the databases. To access the articles, the keywords; central nervous system tumors, primary brain tumors, spinal cord neoplasm, glioma, meningioma, glioblastoma, oligodendroglioma, medulloblastoma, astrocytoma, prevalence, cross-sectional, and outbreak were used. The articles were collected in Endnote software after performing the search without any time limit. To maximize the search comprehensiveness, the list of sources used in all related articles found in mentioned search was manually reviewed.

Inclusion and exclusion criteria of the study

The inclusion and exclusion criteria of this study were designed based on PICOS guidelines. Inclusion criteria for this study included: 1- studies that examined the prevalence of primary CNS tumors, 2- observational studies, and 3- cross-sectional studies. Exclusion criteria included: 1- unrelated study, 2- studies without sufficient data, 3- duplication studies, 4- unclear study methods, 5- interventional studies, 6- case report studies, and 7- studies for which the full text is not available.

Selection and extraction of studies

After transferring all the extracted studies to EndNote software, duplicate articles that were identified were removed. the researchers reviewed the studies by title and abstract by the defined inclusion and exclusion criteria. during the second evaluation process, the full text of the remaining articles was re-examined based on the inclusion and exclusion criteria. During these steps, studies were performed by two researchers independently to minimize bias. If there was a disagreement between the two researchers, the studies were conducted by a third party. After these steps, the approved studies entered the qualitative evaluation stage to evaluate the methodological quality. Information on all final articles submitted to the systematic review and meta-analysis process is extracted from a pre-prepared checklist. This checklist the included article title, first author name, year of publication, place of study, sample size, sample evaluation method, gender, type of study, study population, number of people with CNS tumors in general, and the tumor type.

Qualitative evaluation of studies

Since cross-sectional observational studies were considered the inclusion criteria, the STROBE checklist was used to critique and evaluate the quality of articles approved in the previous stages. This checklist has 22 items, some of which have several sections, so the STROBE checklist contains a total of 32 items that examine different parts of the study body, including the title, abstract, introduction, data collection methods, statistical analysis methods, and presentation of results. Articles that have lost more than 50% of the items defined in the STROBE checklist are considered as poor quality articles due to their high probability of bias and were excluded from the study, so at this stage, studies that were considered qualitatively as studies of good and average methodological quality entered the analysis process. In the present study, based on the evaluation made based on the STROBE checklist, 78 articles were entered into the systematic review and meta-analysis process as good and medium methodological quality studies.

Statistical analysis

The I2 test was used to evaluate the heterogeneity of the selected studies. To investigate the dissemination error due to the high volume of samples included in the study, the Egger test was applied at a significant level of 0.05 and the corresponding funnel plot. Data analysis was performed using Comprehensive Meta-Analysis software (Version 2).

Results

In this systematic review and meta-analysis study, the information of studies conducted about the prevalence of primary central nervous system (CNS) tumors in the world until 29 August 2020 was systematically reviewed according to PRISMA guidelines. Based on the initial search in the database, 2186 possible related articles were identified and transferred to the information management software (EndNote). 535 out of 2186 identified studies were duplicated and excluded. In the screening phase, out of 1651 studies, the remaining 1513 articles were removed by studying the titles and abstracts based on inclusion and exclusion criteria. In the competency evaluation stage, out of 138 studies, the remaining 60 articles were removed by studying the full text of the article based on inclusion and exclusion criteria due to irrelevance. In the qualitative evaluation stage, all 80 studies were confirmed by reading the full text of the article and based on the score obtained from the STROBE checklist (Fig. 1; Table 1).
Table 1
Information of articles
Rows
Name [references]
Country
Year of publication
Participants
Prevalence
1
Seung Hoon Lee [34]
South Korea
2017
654
Germ cell tumors (pituitary adenomas: 6.7%, pineal tumor: 34.5%, Brain tumor: 35%)
2
Yeon-Lim Suh [25]
Korea
2002
3221
Pituitary adenomas: 19%, meningioma: 24%, tumors of neuroepithelial tissue: 31.6%(embryonal tumors: 2.6% MEDULLOBLASTOMA: 1.8%, ependymal tumors: 1.8%, glial tumor of CNS and pineal gland: 2.3%, astrocytic tumors of CNS: 8.9%, oligodendroglial: 3.3%, choroid plexus: 0.4%, glioblastoma: 10.6%), germ cell tumors: 1.7%
3
Yeon-Lim Suh [25]
Korea
2002
2556
Pituitary adenomas: 15.1%, meningioma: 25.1%, tumors of neuroepithelial tissue: 34.9%(glioblastoma: 4.8%, glial tumor of CNS and pineal gland: 0.35%, astrocytic tumors of CNS: 15.9%, oligodendroglial: 4.6%, choroid plexus: 0.4%, embryonal tumors: 3.3%, ependymal tumors: 2.4%) germ cell tumors: 1.7%
4
Anirban Ghosh [42]
India
2004
873
Brain tumor [glioma: 60% (ependymal tumors: 3.2%, astrocytic tumors of CNS: 36.7%, oligodendroglial: 4.9%), meningioma: 11.6%, pineal tumor: 0.2%, medulloblastoma: 1.6%, pituitary adenomas: 4.1%]
5
Axel Tjo¨ rnstrand [43]
Sweden
2014
592
Pituitary adenomas: 100%
6
Adrian F. Daly [44]
Belgium
2006
68
Pituitary adenomas: 100%
7
Kullapat Veerasarn [45]
Thailand
2016
93,810
Pituitary adenomas: 3.8%, meningioma: 15.3%, pineal tumor: 1.9%
8
Kurupath Radhakrishnan [46]
USA
1995
339
Pituitary adenomas: 16.2%, glioma: 29.4% (ependymal tumors: 1.1%, astrocytic tumors of CNS: 24.7%, oligodendroglial: 3.2%), meningioma: 40.1%, schwannoma: 4.4%, medulloblastoma: 1.7%
9
T.B. Johannesen [36]
Norway
2004
14,641
Pituitary adenomas: 9.3%, meningioma: 21.9%, pineal tumor: 0.7%, brain tumor: 60.1%, spinal tumor: 1.9%
10
Yun-Sik Dho [41]
Republic of Korea
2017
11,827
10 pituitary adenomas: 17.9%, meningioma: 37.2%, tumors of neuroepithelial tissue: 13.6% (glioma: 12.6%, ependymal tumors: 0.9%, glial tumor of CNS and pineal gland: 1.07%, astrocytic tumors of CNS: 2.03%, oligodendroglial: 1.2%, choroid plexus: 0.16, glioblastoma: 5.3%, pilocytic astrocytomas : 0.4%), germ cell tumors: 1.07%
11
Ahmad F. Tamimi [47]
Jordan
2015
313
Pituitary adenomas: 9.2%, embryonal tumors: 7.02 (medulloblastoma: 4.7%), meningioma: 26.1%, tumors of neuroepithelial tissue: 37.6 (ependymal tumors: 1.5%, astrocytic tumors of CNS: 9.2%, oligodendroglial: 1.2%, choroid plexus: 0.3%, glioblastoma: 18.8%, pilocytic astrocytomas: 3.8%), schwannoma: 3.8%
12
Leonard T. Kurland [48]
USA
1982
223
Pituitary adenomas: 13%, glioma: 34.9%, meningioma: 39.4%
13
Leonard T. Kurland [48]
USA
1982
189
Pituitary adenomas: 12.1%, glioma: 35.9%, meningioma: 39.6%
14
Chang-Hyun Lee [2]
Korea
2010
5,692
Pituitary adenomas: 13.8, meningioma: 29.6%, tumors of neuroepithelial tissue: 19.3% (glioma: 1.9%, embryonal/primitive /medulloblastoma: 1.2%, ependymal tumors: 1.1%, glioblastoma: 5.9%, astrocytic tumors of CNS: 4.8%, oligodendroglial: 1.05%, choroid plexus: 0.26%)
15
Haley Gittleman [16]
USA
2014
51,125
Pituitary adenomas: 100%
16
NUNG WON CHOI [49]
USA
1970
760
Pituitary adenomas: 2.6%, glioma: 56.7% (ependymal tumors: 2.8%, astrocytic tumors of CNS: 17.5%, Oligodendroglial: 1.3%, glioblastoma: 20.9%, medulloblastoma: 2.5%), meningioma: 6.8%
17
David Gigineishvili
[21]
Georgia
2013
980
Pituitary adenomas: 11.7%, meningioma: 25.9%, tumors of neuroepithelial tissue: 13.1% (glioblastoma: 4.8%, ependymal tumors: 0.4%, astrocytic tumors of CNS: 3.3%, oligodendroglial: 1.22%)
18
D.Gigineishvili [50]
Georgia
2013
473
Pituitary adenomas: 17.9%, meningioma: 45.2%, glioblastoma: 9.9%
19
Ramandeep S. Arora [51]
England
2009
54,336
Pituitary adenomas: 8.8%, meningioma: 15.8%, pineal tumor: 0.38%, tumors of neuroepithelial tissue: 53% (embryonal tumors: 1.5% (medulloblastoma: 1.07%), ependymal tumors: 1.96%, astrocytic tumors of CNS: 35.2% (glioblastoma: 21.7%, pilocytic astrocytomas: 1.68%), oligodendroglial: 12.2%, choroid plexus: 0.18%), tumors of cranial and spinal nerves: 6.8%
20
Alberto Fernandez [52]
England
2010
63
Pituitary adenomas: 100%
21
Giuseppe D 'Alessandro [53]
Italy
1995
178
Pituitary adenomas: 14%, meningioma: 37%, tumors of neuroepithelial tissue: 34.8%
22
Amélie Darlix [54]
France
2017
57,816
Pituitary adenomas: 3.7%, meningioma: 7.1%, tumors of neuroepithelial tissue: 43.5% (glioma: 39.1%, embryonal tumors: 1.6% (medulloblastoma: 0.95%), ependymal tumors: 2.3%, astrocytic tumors of CNS: 26.5% (glioblastoma: 21.4%), oligodendroglial: 5.9%, choroid plexus: 0.3%), germ cell tumors: 0.4%, schwannoma: 8.6%
23
Hideo Nakamura [39]
Japan
2011
5,448
Pituitary adenomas: 17.8%, glioma: 19.5%, meningioma: 36.7%, schwannoma: 9.9%, medulloblastoma: 0.45%
24
Dale L. Preston [37]
Japan
2002
467
Pituitary adenomas: 7.49%, glioma: 9.2%, meningioma: 18.8%, schwannoma: 11.3%
25
Charles A. Stiller [17]
Great Britain (England, Scotland and Wales)
2019
4166
Pituitary adenomas: 1.6%, embryonal tumors: 2.6%, ependymal tumors: 6.98%, meningioma: 1.2%, pineal tumor: 1.1%, astrocytic tumors of CNS: 40.9% (glioblastoma: 3.5%, pilocytic astrocytomas: 20.6%) oligodendroglial: 0.8%, choroid plexus: 2.6%, germ cell tumors: 4%, atypical teratoid/rhabdoid tumors: 1.94%, medulloblastoma: 12.5%
26
Tanya S. Surawicz [55]
USA
1999
20,765
Pituitary adenomas: 8%, meningioma: 25.3%, tumors of neuroepithelial tissue: 51.2% (glioma: 3.6%, embryonal tumors: 1.8%, ependymal tumors: 2.36%, glial tumor of CNS and pineal gland: 1.2%, astrocytic tumors of CNS: 8.1%, oligodendroglial: 2.6%, choroid plexus: 0.3%, glioblastoma: 22.6%, medulloblastoma: 1.8%, pilocytic astrocytomas: 1.78%), spinal tumor and tumors of cranial nerves: 6.5%
27
Emily A.J. Sehmer [19]
England
2014
435
Glioma (astrocytic tumors of CNS: 9.6% (glioblastoma: 86.4%), oligodendroglial: 0.4%)
28
Luc Bauchet [20]
France
2009
1017
Glioma: 51.7% (astrocytic tumors of CNS: 32.3% (glioblastoma: 2.3%, pilocytic astrocytomas: 23.1%), oligodendroglial: 6.5%, ependymal tumors: 8.4%), embryonal tumors: 19% (medulloblastoma: 14.9, atypical teratoid/rhabdoid tumors: 1.08%), glioneuronal tumor: 8.3%, meningioma: 2.3%, pineal gland: 1.08%, choroid plexus: 2.8%, germ cell tumors: 3.5%, Schwannoma: 2.3
29
David J. Cote [56]
USA
2019
97,810
Glioma (ependymal tumors: 6.7%, nonglioblastoma astrocytomas: 20.4, oligodendroglial: 8%, glioblastoma: 57.4%)
30
S Preston-Martin [57]
USA
1989
8612
Glioma: 50.1% (ependymal tumors: 1.3%, astrocytic tumors of CNS: 23.1%, oligodendroglial: 1.5%, glioblastoma: 18.2%, medulloblastoma: 2.2%), meningioma: 28%
31
K. Gousias [58]
Greece
2009
56
Glioma: 100%
32
Faith G. Davis [32]
USA
2001
6908
Glioma: 3.5%, embryonal tumors: 1.4%, ependymal tumors: 1.3%, meningioma: 26.5%, astrocytic tumors of CNS: 6.3%, oligodendroglial: 1.7%, glioblastoma: 22.3%, pilocytic astrocytomas: 1.3%
33
Yoshikazu Okamoto [59]
Switzerland
2004
122
Glioma (oligodendroglial: 40.9%)
34
Emmanuel Desandes [33]
France
2014
3886
Glioma: 6.7%, ependymal tumors: 6.4%, meningioma: 1.5%, oligodendroglial: 4.1%, choroid plexus: 2.7%, glioblastoma: 1.6%, germ cell tumors: 5.6%, atypical teratoid/rhabdoid tumors: 2.4%, medulloblastoma: 13.7%, pilocytic astrocytomas: 21.8%
35
Kenneth R. Hess [60]
USA
2004
22,427
Glioma: 2.8%, astrocytic tumors of CNS: 36.6%, oligodendroglial: 6.04%, glioblastoma: 52.02
36
M. P. W. A. Houben [61]
the Netherlands
2006
11,812
Glioma: (ependymal tumors: 3.2%, oligodendroglial/mixed glioma: 11.8%)
37
Helle Collatz Christensen [18]
DENMARK
2003
11,935
Glioma: 100% (meningioma: 40.59)
38
Janhvi Jaiswal [27]
India
2016
4295
Glioma: 34.1%, ependymal tumors: 2.2%, astrocytic tumors of CNS: 3.1%, oligodendroglial: 9.5%, glioblastoma: 12.9%, pilocytic astrocytomas: 2.07%
39
Faith G. Davis [62]
USA
1996
8,070
Glioma: 5.3%, ependymal tumors: 1.6%, meningioma: 21.1%, pineal tumor: 0.16%, astrocytic tumors of CNS: 19.7%, oligodendroglial: 2.1%, glioblastoma: 25.4%, medulloblastoma: 1.8%, pilocytic astrocytomas: 1.5%
40
Tola MR [63]
Italy
1994
169
Glioma (ependymal tumors: 1.7%, astrocytic tumors of cns: 16.5%, oligodendroglial: 7.6%, glioblastoma: 48.5%)
41
Camille Pouchieu [29]
France
2018
3515
Meningioma: 37.5%, tumors of neuroepithelial tissue: 42.5% (glioma: 4.03%, ependymal tumors: 1.9%, pineal tumor: 0.08%, astrocytic tumors of CNS: 4.2%, oligodendroglial: 0.79%, choroid plexus: 0.28%, glioblastoma: 26.8%, pilocytic astrocytomas: 0.96%), germ cell tumors and cysts: 0.5%, cranial and spinal nerve tumors: 12%,
42
Kimberly R. Porter [64]
USA
2010
18 037
Glioma: 33.2%, meningioma: 32.8%
43
Susan preston-martin [65]
USA
1990
462
Glioma: 28.3%, ependymal tumors: 15.1%, meningioma: 42.8%, astrocytic tumors of CNS: 11.25%
44
Adele Caldarella [30]
Italy
2011
4,417
Embryonal tumors: 0.7%, ependymal tumors: 0.9%, meningioma: 27.8%, pineal tumor: 0.02%, astrocytic tumors of CNS: 25.3%, oligodendroglial: 1.3%, choroid plexus: 0.02%, germ cell tumors: 0.02%
45
Rafael Fuentes-Raspall [66]
Spain
2011
679
Embryonal tumors: 3.5%, ependymal tumors: 1.9%, Astrocytic tumors of CNS: 35.7%, oligodendroglial tumors and mixed histologies: 2.5%, choroid plexus: 0.14%
46
Sarah Khan [67]
United Arab Emirates
2020
744
Embryonal tumors: 13.03%, ependymal tumors: 6.18%, meningioma: 4.1%, astrocytic tumors of CNS: 69.6%(diffuse astrocytic and oligodendroglial tumors: 64.9%), choroid plexus: 0.5%, germ cell tumors: 1.7%
47
Emanuele Crocetti [26]
Austria, Iceland, Ireland, Malta, Norway, Slovakia, Slovenia, Sweden, Northern Ireland, Scotland and Wales and Other 10 countries
2012
44,947
Embryonal tumors: 4.1%, ependymal tumors: 3.59%, astrocytic tumors of CNS: 85.9%, oligodendroglial: 6.4%, choroid plexus: 0.1%
48
Gillian C. Cole [68]
Wales
1989
526
Ependymal tumors: 4.7%, pineal tumor: 0.9%, astrocytic tumors of CNS: 52.6%, oligodendroglial: 6.8%, germ cell tumors: 0.7%, medulloblastoma: 1.7%
49
Kate A. Schellinger [22]
USA
2008
3,226
Spinal tumor: 69.9% (ependymal tumors: 23%, meningioma: 29%)
50
Linh M. Duong [69]
USA
2012
11,712
Ependymal tumors: 21.1%, meningioma: 32.6%, spinal tumor: 26.6%, pilocytic astrocytomas: 1.6%
51
Naseem Ahmed [70]
Pakistan
2007
81
Ependymal tumors: 9.8%, astrocytic tumors of CNS: 35.8%, oligodendroglial: 1.2%, glioblastoma multiforme: 3.7%,
pilocytic astrocytomas: 14.8%
52
Peter Kaatsch [24]
Germany
2001
3268
Ependymal tumors: 10.3%, meningioma: 1.16%, pineal tumor: 1.3%, astrocytic tumors of CNS: 41.7%
53
Therese A. Dolecek [23]
USA
2015
51,065
Meningioma: 100%
54
Bernd Holleczek [71]
Germany
2019
992
Meningioma: 100%
55
S. Zouaoui [72]
France
2018
13,038
Meningioma: 100%
56
Luis Eduardo Werneck de Carvalho [73]
Brazil
2017
949
Meningioma: 24.9%, tumors of neuroepithelial tissue: 40%, germ cell tumors: 0.9%
57
Mousa Taghipour [74]
Iran
2010
371
Meningioma: 100%
58
Lars Klaeboe [75]
Denmark, Finland, Norway and Sweden
2005
18,630
Meningioma: 100%
59
Lona C [31]
Italy
1988
182
Meningioma: 28.5%, tumors of neuroepithelial tissue: 56.04%, germ cell tumors: 1.09%
60
CHRISTOPH BURKHARD [40]
Switzerland
2003
196
Pilocytic astrocytomas: 28%
61
Keishi Makino [76]
Japan
2013
6,615
Pineal tumor: 0.46%, germ cell tumors: 1.05%
62
Donna L. Johnston [77]
Canada
2014
574
Medulloblastoma: 100%
63
Yousef S. Khader [35]
Jordan
2018
2096
Brain tumor: 100%
64
Maria Teresa GIORDANA [78]
Italy
1999
45
Medulloblastoma: 68.8%
65
JIANG Tao [79]
China
2011
636
Brain tumor: 100%
66
S. Cordera [80]
Italy
2002
253
Tumors of neuroepithelial tissue: 35.1%
67
Adalberto Miranda-Filho [81]
Brazil, France
2017
78,034
Primary CNS tumors: 100%
68
Sandrine Elia-Pasquet [82]
France
2004
329
Brain tumor: 92.4%, spinal tumor: 7.5%
69
Birthe Krogh Rasmussen [83]
Denmark
2017
1930
Astrocytic tumors of CNS: 15.5%, oligodendroglial: 5.9%, glioblastoma: 70.6%, pilocytic astrocytomas: 1.8%
70
Hyeon Jin Park [84]
Korea
2016
2,116
Germ cell tumors: 54.3%
71
Rose Lai [85]
USA
2008
454
Medulloblastoma: 100%
72
Agne` s Fleury [86]
France
1997
1376
Astrocytic tumors of CNS: 68.3%
73
Abbas Rezaianzadeh [87]
Iran
2020
1043
Brain tumor: 100%
74
Malene Schjønning Nielsen [28]
Denmark
2009
1,304
Oligodendroglial: 100%
75
Marios K. Georgakis [88]
12 SEE countries (Belarus, Croatia, Cyprus, Malta, Montenegro, Greater Poland, Portugal Central, Portugal North, Romania-Cluj, Romania-Iasi, Serbia Central, Slovenia, Turkey-Izmir and Ukraine)
2017
11,438
Primary CNS tumors: 100%
76
Nicolas R. Smoll [38]
Australia
2012
1372
Medulloblastoma: 100%
77
ARE HELSETH [89]
Norway
1995
10,936
Primary CNS tumors: 100%
78
Stefan L¨ONN [90]
Denmark, Finland, Norway, and Sweden
2004
43,120
Primary CNS tumors: 100%
79
Adah S. Zhang [91]
USA
2017
294,666
Brain tumor: 49.9% (glioblastoma: 44.3%, pilocytic astrocytomas: 3.7%)
80
C A STILLER [92]
UK
1994
12,509
Primary CNS tumors: 100%

Pituitary adenomas

26 studies with a sample size of 331,575 people working on pituitary adenomas were obtained, which its highest prevalence reported by Gittleman et al. [16]. In contrast, the lowest prevalence was reported by Stiller et al. [17] (Table 1). Based on the analysis (I2: 99.6) and publication results bias of Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, heterogeneity of the study was not significant (p: 0.566) Meta-analysis, according to which the prevalence of pituitary adenomas was 12.2 (95% CI 9.4–15.7) (Table 2).
Table 2
Heterogeneity, publication bias, and the overall prevalence of tumors studied in the study based on meta-analysis and random analysis
Tumor type
Number of articles
Sample size
Heterogenicity (I2)
Publication bias (Begg and Mazumdar rank correlation test)
Prevalence (95% CI)
Pituitary adenomas
26
331,575
99.6
0.566
12.2 (95% CI: 9.4–15.7)
Glioma
27
303,967
99.9
0.113
42.8 (95% CI: 29–57.7)
Embryonal tumors
14
207,577
99.3
0.742
3.1 (95% CI: 2.1–4.5)
Ependymal tumors
33
379,800
99.7
0.258
3.2 (95% CI: 2.3–4.4)
Meningioma
42
450,109
99.7
0.438
24.1 (95% CI: 20.5–28.1)
Glial tumor of CNS and pineal gland
17
228,500
99.4
0.692
0.8 (95% CI: 0.4–1.5)
Astrocytic tumors of CNS
33
375,302
99.9
0.744
20.3 (95% CI: 15–26.8)
Oligodendroglial
34
387,350
99.5
0.802
3.9 (95% CI: 3.1–4.9)
Choroid plexus
16
219,897
98.5
0.444
0.4 (95% CI: 0.2–0.7)
Tumors of neuroepithelial tissue
14
162,538
99.8
0.324
34.7 (95% CI: 28.6–41.3)
Glioblastoma
26
616,726
99.9
0.133
17.7 (95% CI: 13.9–22.3)
Germ cell tumors
16
104,207
99.7
0.115
2.6 (95% CI: 0.8–8.2)
Brain tumor
8
314,938
99.2
0.710
70.9 (95% CI: 63.1–77.5)
Spinal tumor
7
108,524
99.9
1.000
12.2 (95% CI: 5–27.1)
Schwannoma
6
65,400
93.3
0.259
6.7 (95% CI: 5.3–8.4)
Medulloblastoma
19
172,593
99.6
0.093
7.7 (95% CI: 4.2–13.6)
Pilocytic astrocytomas
16
427,683
99.7
0.162
3.8 (95% CI: 2.3–6.5)

Glioma

In the study of glioma tumors, 27 studies with a sample size of 303,967 people were obtained. The highest prevalence of which was reported by Christensen et al. [18], and the lowest prevalence by Semher et al. [19] (Table 1). The heterogeneity of the study was not significant according to the analysis (I2 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 (p: 0.113). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to the prevalence of glioma tumor, which was 42.8 (95% CI: 29–57.7) (Table 2).

Embryonal tumors

In the study of embryonal tumors, 14 studies with a sample size of 207,577 people were obtained, the highest prevalence of which was reported by Bauchet et al. [20]; however, the lowest prevalence was reported by Gigineishvili et al. [21] (Table 1). Based on analysis (I2: 99.3) and the results of diffusion bias according to the Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, the heterogeneity of the study was not significant (p: 0.742). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of embryonal tumors was 3.1 (95% CI: 2.1–4.5) (Table 2).

Ependymal tumors

33 studies with a sample size of 379,800 people were obtained working on ependymal tumors, showing the highest prevalence of which was reported by Schlinger et al. [22] and the lowest prevalence by Jiginishvili et al. [21] (Table 1). A study of the heterogeneity of these researches showed the result was insignificant (p: 0.258) based on analysis (I2: 99.7) and diffusion bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of ependymal tumors was 3.2 (95% CI: 2.3–4.4) (Table 2).

Meningioma

In the study of meningioma tumors, 42 studies with a sample size of 450,109 were obtained. The highest prevalence of which was reported by Dolesk et al., [23], and the lowest prevalence by Katesh et al. [24] (Table 1). The heterogeneity study of the reports was insignificant (p: 0.438) according to the analysis (I2: 99.7) and diffusion bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of meningioma was 24.1 (95% CI: 20.5–28.1) (Table 2).

Glial tumor of CNS and pineal gland

In the study of glial tumors of CNS and pineal gland, 17 studies with a sample size of 228,500 people were obtained, showing the highest prevalence of which was reported by Lim Soo et al. [25], and the lowest prevalence was reported by Lim Soo et al. [25] (Table 1). Investigation of heterogeneity in the studies was not significant (p: 0.692), based on analysis (I2: 99.4) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of astrocytic tumors of the CNS was 0.8 (95% CI: 0.4–1.5) (Table 2).

Astrocytic tumors of CNS

In the study of astrocytic tumors of the CNS, 33 studies were obtained with a sample size of 375,302 people, demonstrating the highest prevalence of which was reported by Croust et al. [26]. In contrast, the lowest prevalence was reported by Jesual et al. [27] (Table 1). A study of the heterogeneity of the research showed the result was not significant (p: 0.744), based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in studies of the random-effects model, Meta-analysis was used, according to which the prevalence of astrocytic tumors of the CNS was 20.3 (95% CI: 15–26.8) (Table 2).

Oligodendroglial

In the study of the oligodendroglial tumor, 34 studies with a sample size of 387,350 people were obtained, the highest prevalence of which was reported in the study of Nielsen et al. [28] and the lowest prevalence in the study of Poschio et al. [29] (Table 1). Based on analysis (I2: 99.5) and publication bias results according to Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, it was shown that heterogeneity of these studies was not significant (p: 0.802). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of oligodendroglial tumor was 3.9 (95% CI: 3.1–4.9) (Table 2).

Choroid plexus

In the study of choroid plexus tumors, 16 studies with a sample size of 219,897 people were obtained, the highest prevalence of which was reported by Basht et al. [20], and the lowest prevalence was reported by Caldarella et al. [30] (Table 1). Study heterogeneity of the reports revealed no significant result (p: 0.444) based on analysis (I2: 98.5) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of choroid plexus tumor was 0.4 (95% CI: 0.2–0.7) (Table 2).

Tumors of neuroepithelial tissue

In the study of tumors of neuroepithelial tissue, 14 studies with a sample size of 162,538 people were obtained, the highest prevalence of which was reported by Luna et al. [31], and the lowest prevalence was reported by Jiginishvili et al. [21] (Table 1). Based on analysis (I2: 99.8) and publication bias results obtained by Begg and Mazumdar rank correlation test analysis at a significance level of 0.1, investigation of the heterogeneity showed no significant data (p: 0.324). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of tumors of neuroepithelial tissue was 34.7 (95% CI: 28.6–41.3) (Table 2).

Glioblastoma

In the study of glioblastoma tumors, 26 studies with a sample size of 616,726 people were obtained, showing the highest prevalence of which was reported by Davis et al. [32] and the lowest prevalence was reported by Desandes et al. [33] (Table 1). Study heterogeneity based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significant result (p: 0.133). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of glioblastoma tumor was 17.7 (95% CI: 13.9–22.3) (Table 2).

Germ cell tumors

In the study of germ cell tumors, 16 studies were obtained with a sample size of 104,207 people, revealing the highest prevalence of which was reported by Lee et al. [34] and the lowest prevalence by Calderla et al. [30] (Table 1). The heterogeneity of the study was not significant (p: 0.115) based on analysis (I2: 99.7) and results of publication bias based on the analysis of the Begg and Mazumdar rank correlation test at a significance level of 0.1. Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of germ cell tumors was 2.6 (95% CI: 0.8–8.2) (Table 2).

Brain tumor

In the study done on a brain tumor, 8 studies with a sample size of 314,938 people were obtained, revealing the highest prevalence of which was reported by Ghader et al. [35] and the lowest prevalence was reported by Lee et al. [34] (Table 1). Study heterogeneity based on analysis (I2: 99.2) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.710). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of brain tumors was 70.9 (95% CI: 63.1–77.5) (Table 2).

Spinal tumor

In the study performed on the spinal tumor, 7 studies with a sample size of 108,524 people were obtained, the highest prevalence of which was reported by Schillinger et al. [22], and the lowest prevalence was reported by Johansen et al. [36] (Table 1). Study heterogeneity based on analysis (I2: 99.9) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 1.000). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of spinal tumor was 12.2 (95% CI: 5–27.1) (Table 2).

Schwannoma

In the study of schwannoma tumor, 6 studies with a sample size of 65,400 people were obtained, showing the highest prevalence of which was reported by Preston et al. [37] and the lowest prevalence by Basht et al. [20] (Table 1). Study heterogeneity based on analysis (I2: 93.3) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.259). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis to determine the prevalence of schwannoma tumor was 6.7 (95% CI: 5.3–8.4) (Table 2).

Medulloblastoma

In the study performed on medulloblastoma tumor, 19 studies with a sample size of 172,593 people were achieved, showing the highest prevalence of which was reported by Small et al. [38] and the lowest prevalence was reported by Nakamura et al. [39] (Table 1). Study heterogeneity based on analysis (I2: 99.6) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.093). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of medulloblastoma was 7.7 (95% CI: 4.2–13.6) (Table 2).

Pilocytic astrocytomas

In the study done on pilocytic astrocytomas, 16 studies with a sample size of 427,683 people were obtained, clarifying the highest prevalence of which was reported by Burkard et al. [40] and the lowest prevalence was reported by Doo et al. [41] (Table 1). Study heterogeneity based on analysis (I2: 99.7) and publication bias results based on Begg and Mazumdar rank correlation test analysis at a significance level of 0.1 showed no significance (p: 0.162). Based on high heterogeneity in the studies, a random-effects model was used in the meta-analysis, according to which the prevalence of pilocytic astrocytomas was 3.8 (95% CI: 2.3–6.5) (Table 2).

Discussion

In the present study, the prevalence of primary tumors was investigated worldwide by systematic review and meta-analysis using 78 studies. In his review study, it was found that the highest prevalence of brain tumors is 70.9%. Afterward, neuroepithelial, glioma, meningioma, and glioblastoma tumors have the most significant prevalence, respectively, while finally, medulloblastoma, schwannoma, pilocytic astrocytomas, and oligodendroglial have the least prevalence. The choroid plexus has also the lowest prevalence among primary tumors. In a study conducted by Tamimi et al., In Jordan, the astrocytic glioma tumor was identified as the most common primary tumor, with a prevalence of 37.7% [47]. However, in our study, tumor type was measured as two separate tumors, which ultimately showed that glioma tumors have a prevalence of 31.9% and astrocytic tumors of 21%, which is almost similar to the data obtained from the study done by Tamimi et al. Another study by Johansen et al., it was considered that brain tumors are the most common primary tumors [36] which in our study brain tumors were also measured as the most common primary tumors. In another study by Poschio et al., meningioma and glioblastoma were identified as the most common, with a prevalence of 35% and 26.9%, respectively [29].
Konsel et al. conducted a study to measure the incidence of intracranial tumors in Latin Scotland between 1990 and 1989, which identified 228 primary tumors and 214 secondary tumors. Among the 228 primary tumors, neuroepithelial tumors, which include astrocystic, oligodendroglia, mixed glioma, ependymoma, pineal, and embryonic, were observed in 122 patients (53.5%). Therefore, neuroepithelial tumors were recognized as the most common tumors. Germ cell tumors also showed the lowest prevalence (0.4%). The prevalence study of neuroepithelial tumors is slightly different from our data (34.7%). Our study also presents the lowest prevalence for choroid plexus tumor whose prevalence has not been measured by Consell et al. study [93].
According to studies reported in South Korea, Norway, China, and Jordan, the prevalence of brain tumors was 35, 60.2, 24.56, and 4.4, respectively, which is almost consistent with the results obtained by our study. In most of these studies, brain tumors have a significant prevalence [3436, 79]. Another primary tumor that had a high prevalence in our study was neuroepithelial tumors which were almost consistent with the previously reported results [25, 29, 53, 54]. It was also observed that the prevalence of choroid plexus tumors is consistent with the present study [47, 67].
It has been observed that the prevalence of primary tumors is increasing in some European countries. Various environmental reasons have been put forward for including, including ionizing radiation, some serum compounds such as N nitrous compounds, air pollution, radio spectrum of electromagnetic waves, and ionizing radiation of the brain, which are among the environmental factors increasing the risk of central nervous system primary tumors. Given the industrial nature of the countries, this seems logical. [94] Among non-European countries, Japan also has a significant prevalence of primary tumors due to radiation from the atomic bomb. In one study, schwannoma was the most common tumor in this country [37], and meningioma was identified as the most common primary tumor in the country [39], showing the important impact of environmental factors on the incidence of central nervous system primary tumors.
Among the cases that measured the prevalence according to age and sex, we can mention the study of Martin Preston, in which it was found that the prevalence of primary tumors is higher in women [65]. A study by Joannstrand et al. found that the prevalence of pituitary tumors in women was higher than in men [43]. Prevalence concerning age has been reported in almost similar studies, and those studies have shown that these tumors are more prevalent in middle-aged people [21, 50, 54, 58].

Limitation

One of the limitations of this study is the lack of access to data related to age and gender. Also, the lack of access to full text in some studies was another limitation observed in this study.

Conclusion

As a result, it can be stated that brain tumors are the most common type of primary CNS tumors. It was also observed that tumors involving neuroepithelial cells are more common than other tumors. Since environmental factors are known to be among the factors affecting the prevalence of these tumors, it is necessary to measure the discriminant effect of each of these factors on the prevalence of primary CNS tumors in future studies.

Acknowledgements

By the Student Research Committee of Kermanshah University of Medical Sciences. We would like to thank the esteemed officials of the center for the financial affords of this study.

Declarations

Ethics approval was received from the ethics committee of deputy of research and technology, Kermanshah University of Medical Sciences (IR.KUMS.REC.1400.174).
Not applicable.

Competing interests

The authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Materljan E, et al. Epidemiology of central nervous system tumors in Labin area, Croatia, 1974–2001. Croat Med J. 2004;45(2):206–12. Materljan E, et al. Epidemiology of central nervous system tumors in Labin area, Croatia, 1974–2001. Croat Med J. 2004;45(2):206–12.
2.
Zurück zum Zitat Lee C-H, et al. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010;48(2):145.CrossRef Lee C-H, et al. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010;48(2):145.CrossRef
3.
Zurück zum Zitat Liigant A, et al. Epidemiology of primary central nervous system tumors in Estonia. Neuroepidemiology. 2000;19(6):300–11.CrossRef Liigant A, et al. Epidemiology of primary central nervous system tumors in Estonia. Neuroepidemiology. 2000;19(6):300–11.CrossRef
4.
Zurück zum Zitat Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2008;92(1):87.CrossRef Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2008;92(1):87.CrossRef
5.
Zurück zum Zitat Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin 1998; 48(6): 331–60, 321. Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: advances in knowledge and treatment. CA Cancer J Clin 1998; 48(6): 331–60, 321.
6.
Zurück zum Zitat Chen L, et al. Central nervous system tumors: a single center pathology review of 34,140 cases over 60 years. BMC Clin Pathol. 2013;13(1):14.CrossRef Chen L, et al. Central nervous system tumors: a single center pathology review of 34,140 cases over 60 years. BMC Clin Pathol. 2013;13(1):14.CrossRef
7.
Zurück zum Zitat Johnson KJ, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomark Prev. 2014;23(12):2716.CrossRef Johnson KJ, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomark Prev. 2014;23(12):2716.CrossRef
8.
Zurück zum Zitat Mehta DP, et al. Demographic and histopathologic profile of pediatric patients with primary brain tumors attending a regional cancer center. Indian J Med Paediatr Oncol. 2019;40(5):65. Mehta DP, et al. Demographic and histopathologic profile of pediatric patients with primary brain tumors attending a regional cancer center. Indian J Med Paediatr Oncol. 2019;40(5):65.
9.
Zurück zum Zitat Buckner JC, et al. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–86.CrossRef Buckner JC, et al. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–86.CrossRef
10.
Zurück zum Zitat Ryan CS, et al. Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study. Neuro-Oncol Pract. 2020;7(3):288–98.CrossRef Ryan CS, et al. Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study. Neuro-Oncol Pract. 2020;7(3):288–98.CrossRef
11.
Zurück zum Zitat Malekpourafshar R, et al. The glioblastoma multiforme in Kerman-Iran, 1994–2004. 2006. Malekpourafshar R, et al. The glioblastoma multiforme in Kerman-Iran, 1994–2004. 2006.
12.
Zurück zum Zitat de Robles P, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):776–83.CrossRef de Robles P, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):776–83.CrossRef
13.
Zurück zum Zitat Walker D, et al. Central nervous system tumors. In: Cancer in adolescents and young adults. Springer; 2017. p. 335–81.CrossRef Walker D, et al. Central nervous system tumors. In: Cancer in adolescents and young adults. Springer; 2017. p. 335–81.CrossRef
14.
Zurück zum Zitat Schoenberg BS. The epidemiology of central nervous system tumors. In: Oncology of the nervous system. Springer; 1983. p. 1–29. Schoenberg BS. The epidemiology of central nervous system tumors. In: Oncology of the nervous system. Springer; 1983. p. 1–29.
15.
Zurück zum Zitat Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.CrossRef Moher D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.CrossRef
16.
Zurück zum Zitat Gittleman H, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg. 2014;121(3):527–35.CrossRef Gittleman H, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg. 2014;121(3):527–35.CrossRef
17.
Zurück zum Zitat Stiller CA, et al. Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study. BMC Cancer. 2019;19(1):1–15.CrossRef Stiller CA, et al. Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study. BMC Cancer. 2019;19(1):1–15.CrossRef
18.
Zurück zum Zitat Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery. 2003;52(6):1327–34.CrossRef Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery. 2003;52(6):1327–34.CrossRef
19.
Zurück zum Zitat Sehmer EA, et al. Incidence of glioma in a northwestern region of England, 2006–2010. Neuro Oncol. 2014;16(7):971–4.CrossRef Sehmer EA, et al. Incidence of glioma in a northwestern region of England, 2006–2010. Neuro Oncol. 2014;16(7):971–4.CrossRef
20.
Zurück zum Zitat Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2009;92(1):87–98.CrossRef Bauchet L, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2009;92(1):87–98.CrossRef
21.
Zurück zum Zitat Gigineishvili D, et al. Incidence rates of the primary brain tumours in Georgia–a prospective population-based study. Bull Georg Natl Acad Sci 2013; 7(2). Gigineishvili D, et al. Incidence rates of the primary brain tumours in Georgia–a prospective population-based study. Bull Georg Natl Acad Sci 2013; 7(2).
22.
Zurück zum Zitat Schellinger KA, et al. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008;87(2):173–9.CrossRef Schellinger KA, et al. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008;87(2):173–9.CrossRef
23.
Zurück zum Zitat Dolecek TA, et al. Epidemiology of meningiomas post-Public Law 107–206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015;121(14):2400–10.CrossRef Dolecek TA, et al. Epidemiology of meningiomas post-Public Law 107–206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015;121(14):2400–10.CrossRef
24.
Zurück zum Zitat Kaatsch P, et al. Population-based epidemiologic data on brain tumors in German children. Cancer Interdiscip Int J Am Cancer Soc. 2001;92(12):3155–64. Kaatsch P, et al. Population-based epidemiologic data on brain tumors in German children. Cancer Interdiscip Int J Am Cancer Soc. 2001;92(12):3155–64.
25.
Zurück zum Zitat Suh Y-L, et al. Tumors of the central nervous system in Korea a multicenter study of 3221 cases. J Neurooncol. 2002;56(3):251–9.CrossRef Suh Y-L, et al. Tumors of the central nervous system in Korea a multicenter study of 3221 cases. J Neurooncol. 2002;56(3):251–9.CrossRef
26.
Zurück zum Zitat Crocetti E, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–42.CrossRef Crocetti E, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–42.CrossRef
27.
Zurück zum Zitat Jaiswal J, et al. Spectrum of primary intracranial tumors at a tertiary care neurological institute: a hospital-based brain tumor registry. Neurol India. 2016;64(3):494.CrossRef Jaiswal J, et al. Spectrum of primary intracranial tumors at a tertiary care neurological institute: a hospital-based brain tumor registry. Neurol India. 2016;64(3):494.CrossRef
28.
Zurück zum Zitat Nielsen MS, et al. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol. 2009;11(3):311–7.CrossRef Nielsen MS, et al. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol. 2009;11(3):311–7.CrossRef
29.
Zurück zum Zitat Pouchieu C, et al. Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France). BMC Cancer. 2018;18(1):1–13.CrossRef Pouchieu C, et al. Increasing incidence of central nervous system (CNS) tumors (2000–2012): findings from a population based registry in Gironde (France). BMC Cancer. 2018;18(1):1–13.CrossRef
30.
Zurück zum Zitat Caldarella A, Crocetti E, Paci E. Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neurooncol. 2011;104(2):589–94.CrossRef Caldarella A, Crocetti E, Paci E. Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neurooncol. 2011;104(2):589–94.CrossRef
31.
Zurück zum Zitat Lona C, et al. Incidence of primary intracranial tumors in the province of Bolzano 1980–84. Ital J Neurol Sci. 1988;9(3):237–41.CrossRef Lona C, et al. Incidence of primary intracranial tumors in the province of Bolzano 1980–84. Ital J Neurol Sci. 1988;9(3):237–41.CrossRef
32.
Zurück zum Zitat Davis FG, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3(3):152–8. Davis FG, et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3(3):152–8.
33.
Zurück zum Zitat Desandes E, et al. Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors. Neuro Oncol. 2014;16(7):975–83.CrossRef Desandes E, et al. Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors. Neuro Oncol. 2014;16(7):975–83.CrossRef
34.
Zurück zum Zitat Lee SH, et al. Nationwide population-based incidence and survival rates of malignant central nervous system germ cell tumors in Korea, 2005–2012. Cancer Res Treat. 2017;49(2):494.CrossRef Lee SH, et al. Nationwide population-based incidence and survival rates of malignant central nervous system germ cell tumors in Korea, 2005–2012. Cancer Res Treat. 2017;49(2):494.CrossRef
35.
Zurück zum Zitat Khader YS, et al. The epidemiology and trend of cancer in Jordan, 2000–2013. J Cancer Epidemiol. 2018;2018:1–7.CrossRef Khader YS, et al. The epidemiology and trend of cancer in Jordan, 2000–2013. J Cancer Epidemiol. 2018;2018:1–7.CrossRef
36.
Zurück zum Zitat Johannesen T, et al. Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology. 2004;23(3):101–9.CrossRef Johannesen T, et al. Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology. 2004;23(3):101–9.CrossRef
37.
Zurück zum Zitat Preston DL, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 2002;94(20):1555–63.CrossRef Preston DL, et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 2002;94(20):1555–63.CrossRef
38.
Zurück zum Zitat Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541–4.CrossRef Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541–4.CrossRef
39.
Zurück zum Zitat Nakamura H, et al. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan—20-year study. Int J Clin Oncol. 2011;16(4):314–21.CrossRef Nakamura H, et al. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan—20-year study. Int J Clin Oncol. 2011;16(4):314–21.CrossRef
40.
Zurück zum Zitat Burkhard C, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003;98(6):1170–4.CrossRef Burkhard C, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003;98(6):1170–4.CrossRef
41.
Zurück zum Zitat Dho Y-S, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017;5(1):16.CrossRef Dho Y-S, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017;5(1):16.CrossRef
42.
Zurück zum Zitat Ghosh A, et al. The first cross sectional survey on intracranial malignancy in Kolkata, India: reflection of the state of the art in Southern West Bengal. Asian Pac J Cancer Prev. 2004;5(3):259–67. Ghosh A, et al. The first cross sectional survey on intracranial malignancy in Kolkata, India: reflection of the state of the art in Southern West Bengal. Asian Pac J Cancer Prev. 2004;5(3):259–67.
43.
Zurück zum Zitat Tjörnstrand A, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171(4):519–26.CrossRef Tjörnstrand A, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171(4):519–26.CrossRef
44.
Zurück zum Zitat Daly AF, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–75.CrossRef Daly AF, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–75.CrossRef
45.
Zurück zum Zitat Veerasarn K, Yuthagovit S, Chailorrat A. Prevalence of brain tumor in Thailand from 2005 to 2014: data from the National Health Security Office. J Med Assoc Thai. 2016;99(Suppl 3):S62–73. Veerasarn K, Yuthagovit S, Chailorrat A. Prevalence of brain tumor in Thailand from 2005 to 2014: data from the National Health Security Office. J Med Assoc Thai. 2016;99(Suppl 3):S62–73.
46.
Zurück zum Zitat Radhakrishnan K, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37(1):67–73.CrossRef Radhakrishnan K, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37(1):67–73.CrossRef
47.
Zurück zum Zitat Tamimi AF, et al. Epidemiology of malignant and non-malignant primary brain tumors in Jordan. Neuroepidemiology. 2015;45(2):100–8.CrossRef Tamimi AF, et al. Epidemiology of malignant and non-malignant primary brain tumors in Jordan. Neuroepidemiology. 2015;45(2):100–8.CrossRef
48.
Zurück zum Zitat Kurland LT, et al. The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935–1977. Ann N Y Acad Sci. 1982;381(1):6–16.CrossRef Kurland LT, et al. The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935–1977. Ann N Y Acad Sci. 1982;381(1):6–16.CrossRef
49.
Zurück zum Zitat Choi NW, Schuman LM, Gullen WH. Epidemiology of primary central nervous system neoplasms: I. Mortality from primary central nervous system neoplasms in Minnesota. Am J Epidemiol. 1970;91(3):238–59.CrossRef Choi NW, Schuman LM, Gullen WH. Epidemiology of primary central nervous system neoplasms: I. Mortality from primary central nervous system neoplasms in Minnesota. Am J Epidemiol. 1970;91(3):238–59.CrossRef
50.
Zurück zum Zitat Gigineishvili D, et al. Primary brain tumour epidemiology in Georgia: first-year results of a population-based study. J Neurooncol. 2013;112(2):241–6.CrossRef Gigineishvili D, et al. Primary brain tumour epidemiology in Georgia: first-year results of a population-based study. J Neurooncol. 2013;112(2):241–6.CrossRef
51.
Zurück zum Zitat Arora RS, et al. Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403–13.CrossRef Arora RS, et al. Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403–13.CrossRef
52.
Zurück zum Zitat Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377–82.CrossRef Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377–82.CrossRef
53.
Zurück zum Zitat D’Alessandro G, et al. Epidemiology of primary intracranial tumors in the Valle d’Aosta (Italy) during the 6-year period 1986–1991. Neuroepidemiology. 1995;14(3):139–46.CrossRef D’Alessandro G, et al. Epidemiology of primary intracranial tumors in the Valle d’Aosta (Italy) during the 6-year period 1986–1991. Neuroepidemiology. 1995;14(3):139–46.CrossRef
54.
Zurück zum Zitat Darlix A, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017;131(3):525–46.CrossRef Darlix A, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017;131(3):525–46.CrossRef
55.
Zurück zum Zitat Surawicz TS, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1999;1(1):14–25. Surawicz TS, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1999;1(1):14–25.
56.
Zurück zum Zitat Cote DJ, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125(19):3390–400.CrossRef Cote DJ, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125(19):3390–400.CrossRef
57.
Zurück zum Zitat Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989;8(6):283–95.CrossRef Preston-Martin S. Descriptive epidemiology of primary tumors of the brain, cranial nerves and cranial meninges in Los Angeles County. Neuroepidemiology. 1989;8(6):283–95.CrossRef
58.
Zurück zum Zitat Gousias K, et al. Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005–2007. Neuroepidemiology. 2009;33(2):89–95.CrossRef Gousias K, et al. Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005–2007. Neuroepidemiology. 2009;33(2):89–95.CrossRef
59.
Zurück zum Zitat Okamoto Y, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1):49–56.CrossRef Okamoto Y, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1):49–56.CrossRef
60.
Zurück zum Zitat Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer Interdiscip Int J Am Cancer Soc. 2004;101(10):2293–9. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer Interdiscip Int J Am Cancer Soc. 2004;101(10):2293–9.
61.
Zurück zum Zitat Houben M, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989–2003. Acta Oncol. 2006;45(3):272–9.CrossRef Houben M, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989–2003. Acta Oncol. 2006;45(3):272–9.CrossRef
62.
Zurück zum Zitat Davis FG, et al. Primary brain tumor incidence rates in four United States regions, 1985–1989: a pilot study. Neuroepidemiology. 1996;15(2):103–12.CrossRef Davis FG, et al. Primary brain tumor incidence rates in four United States regions, 1985–1989: a pilot study. Neuroepidemiology. 1996;15(2):103–12.CrossRef
63.
Zurück zum Zitat Tola MR, et al. Intracranial gliomas in Ferrara, Italy, 1976 to 1991. Acta Neurol Scand. 1994;90(5):312–7.CrossRef Tola MR, et al. Intracranial gliomas in Ferrara, Italy, 1976 to 1991. Acta Neurol Scand. 1994;90(5):312–7.CrossRef
64.
Zurück zum Zitat Porter KR, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520–7.CrossRef Porter KR, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520–7.CrossRef
65.
Zurück zum Zitat Preston-Martin S. Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972–1985. Neuroepidemiology. 1990;9(2):106–11.CrossRef Preston-Martin S. Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972–1985. Neuroepidemiology. 1990;9(2):106–11.CrossRef
66.
Zurück zum Zitat Fuentes-Raspall R, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101(1):117–23.CrossRef Fuentes-Raspall R, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101(1):117–23.CrossRef
67.
Zurück zum Zitat Khan S, Kambris MEK, AlShamsi ET. Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study. BMC Neurol. 2020;20(1):1–10.CrossRef Khan S, Kambris MEK, AlShamsi ET. Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study. BMC Neurol. 2020;20(1):1–10.CrossRef
68.
Zurück zum Zitat Cole GC, Wilkins PR, West RR. An epidemiological survey of primary tumours of the brain and spinal cord in South East Wales. Br J Neurosurg. 1989;3(4):487–93.CrossRef Cole GC, Wilkins PR, West RR. An epidemiological survey of primary tumours of the brain and spinal cord in South East Wales. Br J Neurosurg. 1989;3(4):487–93.CrossRef
69.
Zurück zum Zitat Duong LM, et al. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004–2007. Cancer. 2012;118(17):4220–7.CrossRef Duong LM, et al. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004–2007. Cancer. 2012;118(17):4220–7.CrossRef
70.
Zurück zum Zitat Ahmed N, et al. Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev. 2007;8(3):399. Ahmed N, et al. Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev. 2007;8(3):399.
71.
Zurück zum Zitat Holleczek B, et al. Incidence, mortality and outcome of meningiomas: a population-based study from Germany. Cancer Epidemiol. 2019;62: 101562.CrossRef Holleczek B, et al. Incidence, mortality and outcome of meningiomas: a population-based study from Germany. Cancer Epidemiol. 2019;62: 101562.CrossRef
72.
Zurück zum Zitat Zouaoui S, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2018;64(1):15–21.CrossRef Zouaoui S, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2018;64(1):15–21.CrossRef
73.
Zurück zum Zitat Werneck de Carvalho LE, et al. Central nervous system tumours profile at a referral center in the Brazilian Amazon region, 1997–2014. PLoS ONE. 2017;12(4):e0174439.CrossRef Werneck de Carvalho LE, et al. Central nervous system tumours profile at a referral center in the Brazilian Amazon region, 1997–2014. PLoS ONE. 2017;12(4):e0174439.CrossRef
74.
Zurück zum Zitat Taghipour M, Razmkon A, Bakhtazad A. High prevalence of intracranial meningioma in Jewish population in Shiraz, Southern Iran. Neurosurg Q. 2010;20(2):68–70.CrossRef Taghipour M, Razmkon A, Bakhtazad A. High prevalence of intracranial meningioma in Jewish population in Shiraz, Southern Iran. Neurosurg Q. 2010;20(2):68–70.CrossRef
75.
Zurück zum Zitat Klaeboe L, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer. 2005;117(6):996–1001.CrossRef Klaeboe L, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer. 2005;117(6):996–1001.CrossRef
76.
Zurück zum Zitat Makino K, et al. Incidence of primary central nervous system germ cell tumors in childhood: a regional survey in Kumamoto prefecture in southern Japan. Pediatr Neurosurg. 2013;49(3):155–8.CrossRef Makino K, et al. Incidence of primary central nervous system germ cell tumors in childhood: a regional survey in Kumamoto prefecture in southern Japan. Pediatr Neurosurg. 2013;49(3):155–8.CrossRef
77.
Zurück zum Zitat Johnston DL, et al. Incidence of medulloblastoma in Canadian children. J Neurooncol. 2014;120(3):575–9.CrossRef Johnston DL, et al. Incidence of medulloblastoma in Canadian children. J Neurooncol. 2014;120(3):575–9.CrossRef
78.
Zurück zum Zitat Giordana MT, et al. Epidemiology of adult medulloblastoma. Int J Cancer. 1999;80(5):689–92.CrossRef Giordana MT, et al. Epidemiology of adult medulloblastoma. Int J Cancer. 1999;80(5):689–92.CrossRef
79.
Zurück zum Zitat Jiang T, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J. 2011;124(17):2578–83. Jiang T, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J. 2011;124(17):2578–83.
80.
Zurück zum Zitat Cordera S, et al. Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002;249(3):281–4.CrossRef Cordera S, et al. Epidemiology of primary intracranial tumours in NW Italy, a population based study: stable incidence in the last two decades. J Neurol. 2002;249(3):281–4.CrossRef
81.
Zurück zum Zitat Miranda-Filho A, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017;19(2):270–80. Miranda-Filho A, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017;19(2):270–80.
82.
Zurück zum Zitat Elia-Pasquet S, et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiol. 2004;23(3):110–7.CrossRef Elia-Pasquet S, et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiol. 2004;23(3):110–7.CrossRef
83.
Zurück zum Zitat Rasmussen BK, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571–9.CrossRef Rasmussen BK, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571–9.CrossRef
84.
Zurück zum Zitat Park HJ, et al. Incidence and survival of childhood cancer in Korea. Cancer Res Treat. 2016;48(3):869.CrossRef Park HJ, et al. Incidence and survival of childhood cancer in Korea. Cancer Res Treat. 2016;48(3):869.CrossRef
85.
Zurück zum Zitat Lai R. Survival of patients with adult medulloblastoma: a population-based study. Cancer. 2008;112(7):1568–74.CrossRef Lai R. Survival of patients with adult medulloblastoma: a population-based study. Cancer. 2008;112(7):1568–74.CrossRef
86.
Zurück zum Zitat Fleury A, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79(6):1195–202.CrossRef Fleury A, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79(6):1195–202.CrossRef
87.
Zurück zum Zitat Rezaianzadeh A, et al. Spatio-temporal pattern of malignant neoplasm of brain in Fars province IR Iran (2011–2015): a population-based cross sectional study. Clin Epidemiol Glob Health. 2020;8(4):1006–10.CrossRef Rezaianzadeh A, et al. Spatio-temporal pattern of malignant neoplasm of brain in Fars province IR Iran (2011–2015): a population-based cross sectional study. Clin Epidemiol Glob Health. 2020;8(4):1006–10.CrossRef
88.
Zurück zum Zitat Georgakis MK, et al. Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer. 2017;86:46–58.CrossRef Georgakis MK, et al. Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer. 2017;86:46–58.CrossRef
89.
Zurück zum Zitat Helseth A. The incidence of primary CNS neoplasms before and after computerized tomography availability. J Neurosurg. 1995;83(6):999–1003.CrossRef Helseth A. The incidence of primary CNS neoplasms before and after computerized tomography availability. J Neurosurg. 1995;83(6):999–1003.CrossRef
90.
Zurück zum Zitat Lönn S, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer. 2004;108(3):450–5.CrossRef Lönn S, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer. 2004;108(3):450–5.CrossRef
91.
Zurück zum Zitat Zhang AS, et al. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017;19(5):726–35. Zhang AS, et al. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017;19(5):726–35.
92.
Zurück zum Zitat Stiller C, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol. 1994;23(3):458–64.CrossRef Stiller C, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol. 1994;23(3):458–64.CrossRef
93.
Zurück zum Zitat Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61(2):143–50.CrossRef Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90. J Neurol Neurosurg Psychiatry. 1996;61(2):143–50.CrossRef
94.
Zurück zum Zitat Vienne-Jumeau A, Tafani C, Ricard D. Environmental risk factors of primary brain tumors: a review. Revue neurologique. 2019;175(10):664–78.CrossRef Vienne-Jumeau A, Tafani C, Ricard D. Environmental risk factors of primary brain tumors: a review. Revue neurologique. 2019;175(10):664–78.CrossRef
Metadaten
Titel
The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis
verfasst von
Nader Salari
Hooman Ghasemi
Reza Fatahian
Kamran Mansouri
Sadat Dokaneheifard
Mohammad hossain Shiri
Mahvan Hemmati
Masoud Mohammadi
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
European Journal of Medical Research / Ausgabe 1/2023
Elektronische ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01011-y

Weitere Artikel der Ausgabe 1/2023

European Journal of Medical Research 1/2023 Zur Ausgabe